Company Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-06 pm EDT			5-day change	1st Jan Change
30.45 ^CNY	+0.26%		+4.71%	-41.52%

Apr. 26	Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	China Stocks Fall Ahead of March Economic Data Release	MT

Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.

Number of employees: 181

Managers	Title	Age	Since
Xing Hai Li FOU	Founder	61	13-02-04
Yuan Wei Chen CEO	Chief Executive Officer	61	13-02-04
Ze Yan Shi DFI	Director of Finance/CFO	43	21-11-11
Guo Hong CTO	Chief Tech/Sci/R&D Officer	-	23-09-14
Dai Li COO	Chief Operating Officer	43	20-09-20
Xia Li IRC	Investor Relations Contact	-	-

Members of the board	Title	Age	Since
Yuan Wei Chen CEO	Chief Executive Officer	61	13-02-04
Xing Hai Li FOU	Founder	61	13-02-04
Yuan Lun Chen BRD	Director/Board Member	54	20-09-20
Dai Li COO	Chief Operating Officer	43	20-09-20
Ya Guang Zheng BRD	Director/Board Member	53	23-09-14
Yu Quan Wei BRD	Director/Board Member	65	20-09-20
Yong Chen Peng BRD	Director/Board Member	71	20-09-20
Hong Qun Ma BRD	Director/Board Member	41	23-09-14
Wen Li BRD	Director/Board Member	40	23-09-14
Jian Hong Lan CHM	Chairman	40	20-09-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	99,015,598	58,691,836 ( 59.28 %)	0	59.28 %

Name	Equities	%	Valuation
Penghua Fund Management Co., Ltd. 14.36 %	3,249,834	14.36 %	14 M ¥
Bosera Asset Management Co., Ltd. 3.771 %	853,408	3.771 %	4 M ¥
Changsheng Fund Management Co., Ltd. 3.535 %	799,988	3.535 %	3 M ¥
China Fund Management Co., Ltd. 3.137 %	710,000	3.137 %	3 M ¥
Guotai Asset Management Co., Ltd. 1.367 %	309,395	1.367 %	1 M ¥
China Merchants Fund Management Co., Ltd. 1.228 %	277,889	1.228 %	1 M ¥
ABC-CA Fund Management Co., Ltd. 1.167 %	264,059	1.167 %	1 M ¥
Great Wall Fund Management Co., Ltd. 0.9570 %	216,597	0.9570 %	923 635 ¥
Ping An Fund Management Co., Ltd. 0.6325 %	143,169	0.6325 %	610 516 ¥
HSBC Jintrust Fund Management Co. Ltd. 0.5061 %	114,550	0.5061 %	488 476 ¥

Hinova Pharmaceuticals, Inc.

4/F, Bldg 1, No. 2-3, Rongyao Bldg 5 Keyuan South Road

610041, Chengdu

http://www.hinovapharma.com

address Hinova Pharmaceuticals Inc.(688302)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.45

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
HINOVA PHARMACEUTICALS INC.	-41.52%	418M
MODERNA, INC.	+21.74%	46.4B
IQVIA HOLDINGS INC.	-0.97%	41.75B
LONZA GROUP AG	+49.11%	41.37B
CELLTRION, INC.	-3.52%	29.71B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.52B
MEDPACE HOLDINGS, INC.	+31.18%	12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.13B
BIO-TECHNE CORPORATION	+0.39%	12.18B

Other Biotechnology & Medical Research